A Nation-Wide Retrospective Epidemiological Study of Gastroenteropancreatic Neuroendocrine Neoplasms in China Abstract #1346
Introduction: Representative data on the gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) in Chinese patients is rare.
Aim(s): This study aims to create a GEP-NENs profile of Chinese patients.
Materials and methods: Hospitals at tertiary level in each seven geographic region in China were selected. All inpatient GEP-NEN patients with confirmed pathology were included and their information was collected based on the designed case report form. The primary GEP-NEN sites were measured; the epidemiological and clinical information of each tumor site were compared.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Zhang Yu-Qing
Authors: Jin-Hu F, Yu-Qing Z, Su-Sheng S, Yuan-Jia C, Xing-Hua Y, Li-Ming J, Shao-Ming W, Li M, Yu-Tong H, Chang-Yan F, Xi-Bin S, Qing L, Deloso K, Yihebali C, You-Lin Q
To read results and conclusion, please login ...
Further abstracts you may be interested in
#51 Epidemiology of the neuroendocrine tumors diagnosed in Cardarelli Hospital: a retrospective single-institution analysis of 274 cases
Introduction: Neuroendocrine tumors (NETs) are considered rare tumors and are characterized by their ability to produce peptides that cause typical hormonal syndromes. Neuroendocrine tumors consist of a wide spectrum of malignancies with different histology that can arise from distributed neuroendocrine cells in the body. Although these tumors are frequently indolent, they can be aggressive and resistant to therapy. Its incidence in the U.S.A has been rising in the last three decades (Surveillance, Epidemiology, and End Results registry). NETs are more common than generally believed.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Ferdinando Riccardi
#67 Interest of combined chromogranin A and pancreatic polypeptide for diagnosis and follow-up of gastroenteropancreatic endocrine carcinoma
Introduction: Assessment of tumor burden changes is essential for the management of well-differentiated gastroenteropancreatic neuroendocrine carcinoma (GEPNET). Chromogranin A (CgA) is the principal tumor marker for such tumors; however, its use to evaluate morphological tumor progression is not validated. Combined CgA and pancreatic polypeptide (PP) may increase sensitivity in the diagnosis of GEP-NET.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Thomas WALTER
#87 Alterations of E-cadherin, beta-catenin and caveolin-1 expression in gastroenteropancreatic neuroendocrine tumors
Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP NETs) comprise a heterogeneous group of neoplasm with different histological patterns and biological behavior. Only limited information is available on immunohistochemical prognostic factors of disease. Alterations in the cell-cell adhesion system are closely associated with cell invasion and metastasis in many malignancies, including those of endocrine origin. Abnormal expression of E-cadherin and beta-catenin has been reported to play an important role in these processes. Caveolin-1 has recently been identified as a tumor metastasis modifier factor, which might increase the cell metastasis potential through the interaction with E-cadherin. However, the role of caveolin-1 in GEP NETs cell invasion remains unknown.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Vera V Delektorskaya
#106 Gastroenteropancreatic neuroendocrine tumors: single institution clinicopathological study
Introduction: Neuroendocrine cells are widely distributed throughout the body, and neoplasms from these dispersed cells can arise at many sites. They are distinguished into two broad categories: 1) Tumors identified as small cell lung carcinomas with biology and natural history of a high-grade malignancy and characteristics of small cell undifferentiated or anaplastic appearance by light microscopy. The WHO categorizes these tumors as poorly-differentiated neuroendocrine carcinomas; 2) Well-defined neuroendocrine tumors (NETs) with variable, but most lyindolent biologic behavior and characteristic well-differentiated histologic features. The majority arise in the gastrointestinal tract and collectively they are referred as gastroenteropancreatic neuroendocrine tumors (GEP/NETs). They include carcinoid tumors, pancreatic islet cell tumors (gastrinoma, insulinoma, glucagonoma, VIPoma, somatostatinoma), paragangliomas, pheochromocytomas, and medullary thyroid carcinomas. The WHO classifies the GEP/NETs as well-differentiated NETs (carcinoid tumors) if they are noninvasive and have benign behavior or uncertain malignant potential. In contrast, GEP/NETs with characteristics of low-grade malignancy with invasion of the muscularis propria or beyond, or metastases, are characterized as well-differentiated neuroendocrine carcinomas (malignant carcinoids). Pancreatic islet cell tumors, whether functioning or not, are classified as well-differentiated NETs or well-differentiated neuroendocrine carcinomas, due to the (depending on) histologic characteristics. The WHO classification for gastroenteropancreatic NETs based on stage (ie size and presence of metastases) and grade (mitotic rate, perineural and lymphovascular invasion, Ki-67 proliferative index) categorizes them as well-differentiated NETs, e.g., carcinoid tumors, or as well-differentiated neuroendocrine carcinomas.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Michael M. Vaslamatzis
#288 An Observational Registry Collecting Data on Gastroenteropancreatic Neuroendocrine Tumor Patients (GEP-NET Registry) in the Middle East and Asia
Introduction: NET awareness is low in the Middle East and Asia. This registry of GEP NET patients will capture reported outcomes from physicians in clinical practice who treat patients with GEP NET.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Donald YewHee Poon
